Elyxium Wealth LLC Takes $1.71 Million Position in Zoetis Inc. $ZTS

Elyxium Wealth LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,829 shares of the company’s stock, valued at approximately $1,712,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Prosperity Bancshares Inc acquired a new position in Zoetis in the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis during the 1st quarter worth approximately $28,000. Root Financial Partners LLC lifted its position in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the period. Wellington Grp LLC grew its stake in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the last quarter. Finally, Global Assets Advisory LLC purchased a new position in shares of Zoetis in the 1st quarter valued at approximately $38,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $73.64 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock has a 50 day simple moving average of $76.30 and a 200-day simple moving average of $99.01. The company has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the business earned $1.76 earnings per share. The company’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is presently 34.93%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZTS. Piper Sandler cut their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. UBS Group lowered their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Citigroup dropped their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday. Barclays cut their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Finally, Zacks Research downgraded shares of Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.